GLP-1 receptor agonists
GLP-1 receptor agonists (such as semaglutide, liraglutide, and tirzepatide) are prescription medications intended for the treatment of type 2 diabetes and, in specific medical circumstances, for medically supervised weight management. Their use solely for performance-related weight reduction in sport climbing is inappropriate and can lead to the loss of lean muscle mass, impaired strength, inadequate energy availability, and an elevated risk of Relative Energy Deficiency in Sport (REDs). Side effects such as nausea, vomiting, and reduced fueling capacity may further compromise concentration, recovery, and overall performance.
Although GLP-1 medications are not currently prohibited, they are included in the WADA Monitoring Program, meaning that WADA actively tracks their use in athletes to assess patterns of misuse and potential performance-enhancing effects. The Medical and Anti-doping Commission advises extreme caution and reinforces that medically unnecessary use may jeopardise athlete health and wellbeing.
WORLD CLIMBING remains committed to protecting athlete health and therefore strongly advises against off-label use of GLP-1 medications.
